What is Zacks Research’s Estimate for SRPT Q2 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Zacks Research upped their Q2 2026 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued on Monday, October 21st. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $3.32 per share for the quarter, up from their previous forecast of $3.20. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.45 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q3 2026 earnings at $3.31 EPS and FY2026 earnings at $12.86 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period in the prior year, the firm earned ($0.27) earnings per share. The business’s quarterly revenue was up 38.9% compared to the same quarter last year.

Several other equities analysts have also commented on the company. Jefferies Financial Group started coverage on Sarepta Therapeutics in a report on Monday. They issued a “buy” rating and a $165.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday. Citigroup dropped their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $128.42 on Tuesday. The firm has a market capitalization of $12.14 billion, a price-to-earnings ratio of 1,167.45 and a beta of 0.82. The firm’s fifty day simple moving average is $128.97 and its 200-day simple moving average is $132.40. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. GAMMA Investing LLC grew its holdings in shares of Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares during the period. Mather Group LLC. acquired a new stake in Sarepta Therapeutics in the first quarter valued at $28,000. Wealth Enhancement Advisory Services LLC increased its position in shares of Sarepta Therapeutics by 100.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock valued at $647,000 after buying an additional 2,504 shares in the last quarter. Hudson Capital Management LLC acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $220,000. Finally, Commonwealth Equity Services LLC boosted its position in shares of Sarepta Therapeutics by 8.7% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock worth $679,000 after buying an additional 418 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.